PhD Researcher in Organic Chemistry: Join the Inserm LAGEPP Cki-Yon in a 3-year Ph.D. research opportunity focused on the development of radiotracers for targeted radionuclide therapy of melanoma. This exciting project aims to contribute to the advancement of cancer treatment by exploring second-generation melanin-targeted ligands radiolabeled with less restrictive metallic radionuclides for targeted therapy. As a Ph.D. student, you will be responsible for synthesizing and characterizing analogues of ICF01012, conjugated with polyazamacrocycles for metal radionuclide chelation. Your work will involve optimizing radiolabeling procedures and participating in preclinical evaluations of the radiotracers, including stability and selectivity studies, cellular uptake, biodistribution, and antitumor efficacy experiments in relevant mouse models. This project is part of the SIRIC LYriCAN+ program and benefits from the expertise of the IMoST (Clermont-Fd) and LAGEPP (Lyon) laboratories in radiopharmaceutical development.
Job Details:
| Designation | PhD Researcher |
|---|---|
| Research Area | Organic Chemistry, Radiochemistry, Melanoma, Targeted Radionuclide Therapy |
| Location | Inserm LAGEPP Cki-Yon, Lyon, France |
| Eligibility/Qualification | Master’s degree in Chemistry, knowledge of organic chemistry, experimental and theoretical, proficiency in purification and analysis techniques (HPLC, flash chromatography, NMR, mass spectroscopy, etc.), experience in radiochemistry is a plus, proficiency in English, mobility between Clermont-Fd and Lyon research sites required |
Job Description: The recruited Ph.D. student will play a crucial role in advancing our understanding of targeted radionuclide therapy for melanoma. Your responsibilities will include:
- Synthesis and characterization of ICF01012 analogues conjugated with polyazamacrocycles for metal radionuclide chelation.
- Optimization of radiolabeling procedures.
- Participation in preclinical evaluations, including stability and selectivity studies, cellular uptake, biodistribution, and antitumor efficacy experiments in mouse models.
- Collaboration with experts in the field to contribute to groundbreaking research in cancer therapy.
How to Apply: Interested candidates should submit the following documents via email to Dr. Aurelie Maisonial-Besset at aurelie.maisonial@uca.fr:
- CV
- Letter of Motivation
- Support letter from the master supervisor
- Transcripts of Master 1 and 2 degrees
Application Deadline: 30 November 2023
Funding: This Ph.D. position is funded by the French National Cancer Institute (INCA) as part of the SIRIC LYriCAN+ program.
Ph.D. Supervisor and Host Laboratory: Dr. Aurelie Maisonial-Besset Email: aurelie.maisonial@uca.fr Tel: +33(0)473150803 UMR 1240 IMoST Uni. Clermont Auvergne/Inserm
